|
Market Closed -
NYSE
16:00:03 2026-08-31 EDT
|
5-day change | 1st Jan Change | ||
| 1.170 USD | +2.63% |
|
+17.40% | -66.86% |
| 08-14 | ADC Therapeutics Balances LOTIS-5 Regulatory Risk With LOTIS-7 Opportunity, RBC Says | MT |
| 08-13 | ADC Therapeutics SA, Q2 2026 Earnings Call, Aug 13, 2026 |
Turnover - Evolution of Analysts' Estimates
Earnings Per Share (EPS) - Evolution of Analysts' Estimates
EBIT - Evolution of Analysts' Estimates
| 1m. Revenue rev. | 1y. Revenue rev. | 1y. EPS revision | ||
|---|---|---|---|---|
 | ||||
| ||||
| ||||
| ||||
| ||||
| ||||
| ||||
| ||||
| ||||
| ||||
| Average | ||||
| Weighted average by Cap. |
Turnover
Earnings Per Share (EPS)
EBIT
- Stock Market
- Stocks
- ADCT Stock
- Consensus ADC Therapeutics SA
- Estimates Revisions
Select your edition
All financial news and data tailored to specific country editions
